Enzalutamide for triple negative breast cancer
Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. These appear to be only phase II trials, as the ENDEAR trial never accrued. However, Pfizer and Astellas have given up their efforts to obtain and indication and stopped doing trials for it. Their researchers decided there was a need to better understand the role of androgen signaling in breast cancer for the AR inhibitor to work potentially. Krupp et
There is a clinical trial: NCT01889238, Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer, and others.
Tiffany A. Traina et al, Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology Volume 36, Number 9, 2016 https://doi.org/10.1200/JCO.2016.71.3495
https://www.fiercepharma.com/pharma/a-blow-to-pfizer-partner-astellas-gives-up-trials-xtandi-breast-cancer, Accessed 8/6/2024
Ian Krop et al, A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer.. Clin Cancer Res (2020) 26 (23): 6149–6157.